Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Purpose: The human endogenous retrovirus (HERV-K) envelope (env) protein is a tumor-associated antigen (TAA) expressed on melanoma but not normal cells. This study was designed to engineer a chimeric antigen receptor (CAR) on T-cell surface, such that they target tumors in advanced stages of melanoma. Experimental Design: Expression of HERV-K protein was analyzed in 220 melanoma samples (with various stages of disease) and 139 normal organ donor tissues using immunohistochemical (IHC) analysis. HERV-K env–specific CAR derived from mouse monoclonal antibody was introduced into T cells using the transposon-based Sleeping Beauty (SB) system. HERV-K env–specific CAR+ T cells were expanded ex vivo on activating and propagating cells (AaPC) and characterized for CAR expression and specificity. This includes evaluating the HERV-K–specific CAR+ T cells for their ability to kill A375-SM metastasized tumors in a mouse xenograft model. Results: We detected HERV-K env protein on melanoma but not in normal tissues. After electroporation of T cells and selection on HERV-K+ AaPC, more than 95% of genetically modified T cells expressed the CAR with an effector memory phenotype and lysed HERV-K env+ tumor targets in an antigen-specific manner. Even though there is apparent shedding of this TAA from tumor cells that can be recognized by HERV-K env–specific CAR+ T cells, we observed a significant antitumor effect. Conclusions: Adoptive cellular immunotherapy with HERV-K env–specific CAR+ T cells represents a clinically appealing treatment strategy for advanced-stage melanoma and provides an approach for targeting this TAA on other solid tumors. Clin Cancer Res; 21(14); 3241–51. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“This appears less than that reported after virus-mediated transduction of T cells to express a CAR (28).”
BackgroundSubramanian, R. P., Wildschutte, J. H., Russo, C., & Coffin, J. M. (2011) · Retrovirology · doi:10.1186/1742-4690-8-90 · Cited by 439
Reconstitution of an Infectious Human Endogenous Retrovirus
Lee, Y. N., & Bieniasz, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030010 · Cited by 311 · cited 2×
“from the tumor cell membrane as immature provirus (39, 40).”
BackgroundBioengineering T cells to target carbohydrate to treat opportunistic fungal infection
Kumaresan, P. R., Manuri, P. R., Albert, N. D., Maiti, S., Singh, H., Mi, T., Roszik, J., Rabinovich, B., Olivares, S., Krishnamurthy, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312789111 · Cited by 237
Self-citationBoller, K., König, H., Sauter, M., Mueller-Lantzsch, N., Löwer, R., Löwer, J., & Kurth, R. (1993) · Virology · doi:10.1006/viro.1993.1487 · Cited by 188
Human endogenous retrovirus HERV-K113 is capable of producing intact viral particles
Boller, K., Schönfeld, K., Lischer, S., Fischer, N., Hoffmann, A., Kurth, R., & Tönjes, R. R. (2008) · Journal of General Virology · doi:10.1099/vir.0.83534-0 · Cited by 138
Cited by
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
“Moreover, ERV-K env proteins have been shown to increase immunotherapeutic potential of melanoma, breast, and ovarian cancer patients (Rycaj et al., 2015; Wang-Johanning et al., 2012; Cooper et al., 2015).”
Resurrection of endogenous retroviruses during aging reinforces senescence
Liu, X., Liu, Z., Wu, Z., Ren, J., Fan, Y., Sun, L., Cao, G., Niu, Y., Zhang, B., Ji, Q., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.017 · Cited by 390
Combining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 309
Human endogenous retroviruses and cancer
María, G.-C., Paola, I., Niki, K., Mariacarmela, S., Julià, B., & Rafael, R. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0080 · Cited by 100
Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells
Kumaresan, P. R., da Silva, T. A., & Kontoyiannis, D. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01939 · Cited by 85
Self-citation
Metadata
- Authors
- Krishnamurthy, J., Rabinovich, B. A., Mi, T., Switzer, K. C., Olivares, S., Maiti, S. N., Plummer, J. B., Singh, H., Kumaresan, P. R., Huls, H. M., Wang-Johanning, F., & Cooper, L. J. N.
- Venue
- Clinical Cancer Research
- Published
- 2015-07-14
- Volume
- 21
- Issue
- 14
- Pages
- 3241-3251
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2098378506
- Cited by
- 119
- References
- 8
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-3197
- The paper
- Krishnamurthy, J., Rabinovich, B. A., Mi, T., Switzer, K. C., Olivares, S., Maiti, S. N., Plummer, J. B., Singh, H., Kumaresan, P. R., Huls, H. M., Wang-Johanning, F., & Cooper, L. J. N. (2015). Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-3197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.